NewAmsterdam Gross Profit from 2010 to 2024

NAMS Stock

26.19 7.67 41.41%

NewAmsterdam Pharma Gross Profit yearly trend continues to be comparatively stable with very little volatility. Gross Profit will likely drop to about 12.1 M in 2024. Gross Profit is the profit NewAmsterdam Pharma makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. View All Fundamentals

Gross Profit

First Reported

2010-12-31

Previous Quarter

12.8 M

Current Value

12.1 M

Quarterly Volatility

24.7 M

Credit Downgrade

Yuan Drop

Covid

Check NewAmsterdam Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NewAmsterdam Pharma's main balance sheet or income statement drivers, such as Tax Provision of 28.4 K, Net Interest Income of 3.6 M or Interest Income of 11.8 M, as well as many indicators such as Price To Sales Ratio of 75.5, Dividend Yield of 0.0 or PTB Ratio of 3.34. NewAmsterdam financial statements analysis is a perfect complement when working with NewAmsterdam Pharma Valuation or Volatility modules.

Check out the analysis of NewAmsterdam Pharma Correlation against competitors.

For more information on how to buy NewAmsterdam Stock please use our How to Invest in NewAmsterdam Pharma guide.

Latest NewAmsterdam Pharma's Gross Profit Growth Pattern

Below is the plot of the Gross Profit of NewAmsterdam Pharma over the last few years. Gross profit is a required income statement account that reflects total revenue of NewAmsterdam Pharma minus its cost of goods sold. It is profit before NewAmsterdam Pharma operating expenses, interest payments and taxes. Gross profit is also known as gross margin. It is the profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. NewAmsterdam Pharma's Gross Profit historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in NewAmsterdam Pharma's overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 0

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Gross Profit

Timeline

NewAmsterdam Gross Profit Regression Statistics

	Arithmetic Mean	8,041,236
	Geometric Mean	64,354
	Coefficient Of Variation	307.11
	Mean Deviation	12,889,270
	Median	(14,558)
	Standard Deviation	24,695,170
	Sample Variance	609.9T
	Range	95.9M
	R-Value	0.41
	Mean Square Error	543.8T
	R-Squared	0.17
	Significance	0.12
	Slope	2,290,143
	Total Sum of Squares	8537.9T

NewAmsterdam Gross Profit History

	2024	12.1 M
	2023	12.8 M
	2022	95.9 M

Other Fundumenentals of NewAmsterdam Pharma

Gross Profit Margin

NewAmsterdam Pharma Gross Profit component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Net Invested Capital	Short Long Term Debt	Total Current Assets	Capital Stock	Net Working Capital	Short Term Debt	Common Stock	Property Plant Equipment	Current Deferred Revenue	Net Receivables	Good Will	Intangible Assets
Total Assets		1.0	0.82	-0.98	-0.75	0.89	0.93	1.0	-0.48	1.0	0.77	1.0	-0.83	0.77	0.82	0.99	-0.95	-0.48	-0.55
Total Stockholder Equity	1.0		0.82	-0.98	-0.74	0.88	0.91	1.0	-0.46	0.99	0.79	1.0	-0.83	0.79	0.82	0.99	-0.94	-0.46	-0.52
Net Tangible Assets	0.82	0.82		-0.88	-0.85	0.94	0.78	0.81	-0.68	0.84	0.46	0.84	-1.0	0.46	0.95	0.8	-0.85	-0.68	-0.72
Net Debt	-0.98	-0.98	-0.88		0.85	-0.93	-0.94	-0.98	0.63	-0.99	-0.66	-0.99	0.87	-0.66	-0.83	-0.99	0.98	0.63	0.68
Retained Earnings	-0.75	-0.74	-0.85	0.85		-0.9	-0.88	-0.73	0.9	-0.8	-0.17	-0.78	0.8	-0.17	-0.73	-0.77	0.92	0.9	0.96
Accounts Payable	0.89	0.88	0.94	-0.93	-0.9		0.93	0.87	-0.63	0.92	0.47	0.92	-0.93	0.47	0.94	0.85	-0.93	-0.63	-0.76
Total Liab	0.93	0.91	0.78	-0.94	-0.88	0.93		0.91	-0.61	0.95	0.5	0.94	-0.76	0.5	0.78	0.91	-0.97	-0.61	-0.75
Net Invested Capital	1.0	1.0	0.81	-0.98	-0.73	0.87	0.91		-0.46	0.99	0.79	1.0	-0.81	0.79	0.81	0.99	-0.94	-0.46	-0.52
Short Long Term Debt	-0.48	-0.46	-0.68	0.63	0.9	-0.63	-0.61	-0.46		-0.52	0.1	-0.51	0.61	0.1	-0.44	-0.55	0.71	1.0	0.94
Total Current Assets	1.0	0.99	0.84	-0.99	-0.8	0.92	0.95	0.99	-0.52		0.72	1.0	-0.84	0.72	0.84	0.98	-0.97	-0.52	-0.6
Capital Stock	0.77	0.79	0.46	-0.66	-0.17	0.47	0.5	0.79	0.1	0.72		0.74	-0.52	1.0	0.55	0.75	-0.54	0.1	0.1
Net Working Capital	1.0	1.0	0.84	-0.99	-0.78	0.92	0.94	1.0	-0.51	1.0	0.74		-0.84	0.74	0.84	0.98	-0.96	-0.51	-0.58
Short Term Debt	-0.83	-0.83	-1.0	0.87	0.8	-0.93	-0.76	-0.81	0.61	-0.84	-0.52	-0.84		-0.52	-0.96	-0.79	0.83	0.61	0.65
Common Stock	0.77	0.79	0.46	-0.66	-0.17	0.47	0.5	0.79	0.1	0.72	1.0	0.74	-0.52		0.55	0.75	-0.54	0.1	0.1
Property Plant Equipment	0.82	0.82	0.95	-0.83	-0.73	0.94	0.78	0.81	-0.44	0.84	0.55	0.84	-0.96	0.55		0.75	-0.79	-0.44	-0.56
Current Deferred Revenue	0.99	0.99	0.8	-0.99	-0.77	0.85	0.91	0.99	-0.55	0.98	0.75	0.98	-0.79	0.75	0.75		-0.96	-0.55	-0.58
Net Receivables	-0.95	-0.94	-0.85	0.98	0.92	-0.93	-0.97	-0.94	0.71	-0.97	-0.54	-0.96	0.83	-0.54	-0.79	-0.96		0.71	0.78
Good Will	-0.48	-0.46	-0.68	0.63	0.9	-0.63	-0.61	-0.46	1.0	-0.52	0.1	-0.51	0.61	0.1	-0.44	-0.55	0.71		0.94
Intangible Assets	-0.55	-0.52	-0.72	0.68	0.96	-0.76	-0.75	-0.52	0.94	-0.6	0.1	-0.58	0.65	0.1	-0.56	-0.58	0.78	0.94

Click cells to compare fundamentals

About NewAmsterdam Pharma Financial Statements

NewAmsterdam Pharma shareholders use historical fundamental indicators, such as Gross Profit, to determine how well the company is positioned to perform in the future. Although NewAmsterdam Pharma investors may analyze each financial statement separately, they are all interrelated. The changes in NewAmsterdam Pharma's assets and liabilities, for example, are also reflected in the revenues and expenses on on NewAmsterdam Pharma's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

		Last Reported	Projected for Next Year
	Gross Profit	12.8 M	12.1 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for NewAmsterdam Stock Analysis

When running NewAmsterdam Pharma's price analysis, check to measure NewAmsterdam Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NewAmsterdam Pharma is operating at the current time. Most of NewAmsterdam Pharma's value examination focuses on studying past and present price action to predict the probability of NewAmsterdam Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NewAmsterdam Pharma's price. Additionally, you may evaluate how the addition of NewAmsterdam Pharma to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC